Press Releases

Revenue Growth of 9.1% Year-over-Year

Reaffirms FY 2024 Guidance

NEW YORK--(BUSINESS WIRE)-- Emerald Holding, Inc. (NYSE: EEX) (“Emerald” or the “Company”), America’s largest producer of trade shows and their associated conferences, content and commerce, today reported financial results for the first quarter ended March 31, 2024.

Financial Highlights

• Revenues of $133.4 million for the first quarter 2024, an increase of $11.1 million, or 9.1% over... (continue reading...)

FORM 8.3

PUBLIC DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)

• Fresh data from Global Blue reveals that the global dynamic recovery for Tax Free Shopping accelerated across Continental Europe and Asia Pacific.
• Globally, issued Sales in Store like-for-like recovery reached 153%1 in April 2024 compared to the same period in 2019, vs. 140%1 in Q1 2024.

SIGNY, Switzerland--(BUSINESS WIRE)-- An accelerating worldwide recovery, compared to 2019 levels

In Continental Europe, April 2024 recovery is ahead of Q1 ‘24 recovery,... (continue reading...)

• First quarter GAAP EPS from continuing operations of $0.54 compared to $0.23 in the prior year quarter
• First quarter adjusted EPS of $0.76 exceeded guidance of $0.68 primarily as a result of better-than-expected customer demand from defense applications and lower raw material costs
• First quarter adjusted EPS increased 21% over the prior year driven by improved margins from lower raw material costs and favorable mix, and lower net interest expense
• Revised 2024 full-year... (continue reading...)

NGN-401 has been generally well-tolerated by first three patients dosed, with three to nine months of follow-up

No signs or symptoms of overexpression toxicity, including in one patient with a mild variant predicted to result in residual MeCP2 expression

Neurogene remains on track to provide interim efficacy data from the trial in 4Q:24

NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic... (continue reading...)